Data as of Dec 10
| -0.14 / -3.47%|
The 2 analysts offering 12-month price forecasts for KaloBios Pharmaceuticals Inc have a median target of 13.00, with a high estimate of 15.00 and a low estimate of 11.00. The median estimate represents a +234.19% increase from the last price of 3.89.
The current consensus among 3 polled investment analysts is to Buy stock in KaloBios Pharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.